DBV Technologies S.A. (EPA:DBV)
France · Delayed Price · Currency is EUR 2.874
+0.092 (3.31%)
Jun 23, 2026, 5:35 PM CET
DBV Technologies Market Cap
DBV Technologies has a market cap or net worth of €823.23 million as of June 23, 2026. Its market cap has increased by 279.59% in one year.
Market Cap
823.23M
Enterprise Value
629.74M
Revenue
4.97M
Ranking
n/a
PE Ratio
n/a
Stock Price
€2.87
Market Cap Chart
Since March 29, 2012, DBV Technologies's market cap has increased from 79.23M to 823.23M, an increase of 939.07%. That is a compound annual growth rate of 17.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 23, 2026 | 850.46M | 25.42% |
| Dec 31, 2025 | 678.09M | 949.56% |
| Dec 31, 2024 | 64.61M | -63.70% |
| Dec 29, 2023 | 177.98M | -39.80% |
| Dec 30, 2022 | 295.62M | 75.76% |
| Dec 31, 2021 | 168.19M | -29.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ABIVAX Société Anonyme | 6.78B |
| Nanobiotix | 1.54B |
| MedinCell | 864.57M |
| Inventiva | 634.55M |
| Genfit | 530.82M |
| Valneva SE | 437.14M |
| Transgene | 205.96M |
| Cellectis | 193.85M |